antisense

Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Sarepta’s Vyondys 53 and Amondys 45 failed to show a statistically significant difference versus placebo on a key measurement of DMD patient mobility.

Angus Liu Nov 4, 2025 7:56am

Collage poster study of businessmen picture chart arrow goes up

Novartis, Sarepta tipped to drive genomic therapy sales boom

May 15, 2025 12:18pm

Biogen bets $10M on implant to improve delivery of Spinraza

Jan 10, 2023 7:25am